Melfalan
Tampilan
Nama sistematis (IUPAC) | |
---|---|
4-[bis(2-Chloroethyl)amino]-L-phenylalanine | |
Data klinis | |
Nama dagang | Alkeran, Evomela, Phelinun, others |
AHFS/Drugs.com | monograph |
MedlinePlus | a682220 |
Data lisensi | US Daily Med:pranala |
Kat. kehamilan | ? |
Status hukum | ℞-only (US) |
Rute | By mouth, intravenous, intra-arterial |
Data farmakokinetik | |
Bioavailabilitas | 25–89% (By mouth) |
Metabolisme | Hydrolysis to inactive metabolites |
Waktu paruh | 1.5 ± 0.8 hours |
Ekskresi | Kidney (IV: 5.8–21.3%) |
Pengenal | |
Nomor CAS | 148-82-3 |
Kode ATC | L01AA03 |
PubChem | CID 460612 |
Ligan IUPHAR | 7620 |
DrugBank | DB01042 |
ChemSpider | 405297 |
UNII | Q41OR9510P |
KEGG | D00369 |
ChEBI | CHEBI:28876 |
ChEMBL | CHEMBL852 |
Sinonim | (2S)-2-amino-3-{4-[bis(2-chloroethyl)amino]phenyl}propanoic acid |
Data kimia | |
Rumus | C13H18Cl2N2O2 |
|
Melfalan adalah obat golongan agen antineoplastik sitotoksik. Melfalan bisa digunakan dalam tata laksana mieloma multipel seperti, kanker payudara, karsinoma ovarium, polisitemia vera, adenokarsinoma ovarium lanjut, melanoma, sarkoma jaringan lunak, atau neuroblastoma.[1]
Referensi
[sunting | sunting sumber]- ^ "Melphalan". go.drugbank.com (dalam bahasa Inggris). Diakses tanggal 2023-10-26.